Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Sellas Life Sciences Group Inc
RXK3Current price
1.26 EUR
+0.12 EUR (+10.30%)
Last closed
1.35 USD
Company
www.sellaslifesciences.com
ISIN
US81642T2096
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
80 415 624 USD
Yield for 12 month
+39.94 %
1Y
3Y
5Y
10Y
15Y
RXK3
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. Address: Times Square Tower, New York, NY, United States, 10036
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
5.83 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
+1 000 000 USD
Current Quarter
–
Last Quarter
–
Current Year
–
Last Year
+900 000 USD
Current Quarter
–
Last Quarter
–
Key Figures RXK3
1 year
3 years
5 years
10 years
EBITDA
–
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-129.15 %
PEG Ratio
–
Return On Equity TTM
-888.06 %
Wall Street Target Price
5.83 USD
Revenue TTM
–
Book Value
0.05 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-82.5 %
Dividend Yield
–
Gross Profit TTM
900 000 USD
Earnings per share
-0.9 USD
Diluted Eps TTM
-0.9 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics RXK3
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History RXK3
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:50
Payout Ratio
–
Last Split Date
08.11.2019
Dividend Date
08.11.2019
Stock Valuation RXK3
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
20.8445
Price Sales TTM
26.8951
Enterprise Value EBITDA
-1.7104
Price Book MRQ
27.1641
Financials RXK3
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators RXK3
For 52 weeks
0.5 USD
1.72 USD
50 Day MA
1.23 USD
Shares Short Prior Month
8 176 719
200 Day MA
1.2 USD
Short Ratio
12.41
Shares Short
6 084 267
Short Percent
9.48 %
BeatStart